Ocular Surface Disease (OSD), also known as Dry Eye Disease (DED) is a very complex condition that is chronic and progressive.

There are two primary types of dry eye disease: Evaporative and Aqueous deficient.
Evaporative DED is caused by Meibomian gland dysfunction and is present in over 80% of cases. Cases of purely aqueous deficient DED are fairly rare, occurring about 10% of the time.

Dry Eye Syndrome and Blepharitis are two components of Ocular Surface Disease (OSD). Dry Eye Syndrome refers to a group of disorders of the tear film that result from decreased tear production and/or increased tear evaporation. Blepharitis, or inflammation along the surface of the eyelid, also contributes to OSD by increasing tear evaporation.

The common causes of Dry eye disease include Digital device use, Aging, Contact lens wear, Hormonal changes in women, Environmental factors and certain diseases like arthritis, lupus and thyroid diseases.

The symptoms include Blurry/fluctuating vision, Red eyes, Burning, Itching, Foreign body sensation, gritty, sandy feeling, Light sensitivity, Excessive tearing, Pain or soreness in or around eyes, Tired eyes, Contact lens discomfort or intolerance, Seasonal allergies.

THE KERATOGRAPH is one of several advanced diagnostic instruments and tests our doctors use to diagnose your dry eye disease accurately to help develop your individualized treatment plan. The test results allow your doctor to objectively view the tear film and the health of your tear glands and to measure the tear evaporation rate.

The journal invites different types of articles including original research articles, review articles, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication.

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing.

Manuscripts can be uploaded directly through mail id: ophthalmologist@eclinicalsci.com or forwarded to the Editorial Office at https://www.pulsus.com/ophthalmologist-clinical-therapeutic-journal.html

How we work:
• After submission, an acknowledgment with manuscript number is sent to the corresponding author within 7 working days.
• A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:
Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.
Easy Article Sharing: Our open-access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with an appropriate citation in addition to the retention of content copyright by the author.
Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.
Colour Art: In a world of black & white journal articles, high-quality full-colour images make your article stand out from the crowd and tell a complete story, increasing readers and citations.
Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.
Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.


Media Contact:
Sarah Rose
Journal Manager
The Ophthalmologist: Clinical and Therapeutic Journal
Email: ophthalmologist@eclinicalsci.com